Mr. Adrian Mendes reports

PERIMETER MEDICAL IMAGING AI ANNOUNCES PATIENT RANDOMIZATION UNDERWAY AT CLINICAL TRIAL SITE AT MAYO CLINIC IN FLORIDA

Patient randomization is under way at Mayo Clinic in Florida, the most recent clinical site to be initiated as part of a continuing multicentre, randomized two-arm pivotal clinical trial evaluating the investigational Perimeter B-Series OCT (optical coherence tomography) combined with Perimeter Medical Imaging AI Inc.'s proprietary ImgAssist AI (artificial intelligence) software.

Dr. Sarah Butler, Perimeter's vice-president, clinical and medical affairs, stated: "Patient recruitment and randomization is under way at the Mayo Clinic in Florida, which is one of the sites where we are studying the combination of the Perimeter B-Series medical imaging platform with artificial intelligence software. Combining high-resolution optical coherence tomography with AI algorithms can potentially help surgeons better identify regions of interest during breast-conserving surgeries, with the aim of improving patient outcomes and reducing health care costs."

Adrian Mendes, Perimeter's chief executive officer, stated: "We are pleased that we continue to advance our ongoing pivotal clinical trial, supporting our goal to expedite the development of our next-gen AI technology. With its potential to become the new standard for specimen imaging technology during breast conservation surgery, our hope is that the data generated from this study will support the commercialization of Perimeter B-Series."

About Perimeter Medical Imaging AI Inc.

Based in Toronto, Canada, and Dallas, Tex., Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultrahigh-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the United States, the company's FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents the company's next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to $7.4-million (U.S.) awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol, PINK, is a reference to the pink ribbons used during Breast Cancer Awareness Month.

We seek Safe Harbor.